leadf
logo-loader
NASDAQ:EXAS

Exact Sciences

Receive alerts
Market:
NASDAQ
Market Cap:
$11.63 billion
Price
77.47 USD
Change
3.45%
52 weeks high
113.03
52 weeks low
35.27

In brief

Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradication of colorectal cancer. As part of this mission we are proud to introduce Cologuard. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home.